154 related articles for article (PubMed ID: 21123151)
1. Gemox: a widely useful therapy against solid tumors-review and personal experience.
Meriggi F; Zaniboni A
J Chemother; 2010 Oct; 22(5):298-303. PubMed ID: 21123151
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].
Shi YX; Xu RH; Jiang WQ; Zhang L; Lin TY; Li YH; Xia ZJ; Luo HY; Han B; Wang F; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1381-4. PubMed ID: 18076807
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Lee JL; Ahn JH; Choi MK; Kim Y; Hong SW; Lee KH; Jeong IG; Song C; Hong BS; Hong JH; Ahn H
Br J Cancer; 2014 May; 110(10):2472-8. PubMed ID: 24736579
[TBL] [Abstract][Full Text] [Related]
8. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM
Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
Li J; Merl M; Lee MX; Kaley K; Saif MW
Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Skarlos D
Ann Oncol; 2004 Mar; 15(3):493-7. PubMed ID: 14998855
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Kalykaki A; Papakotoulas P; Tsousis S; Boukovinas I; Kalbakis K; Vamvakas L; Kotsakis A; Vardakis N; Papadopoulou P; Georgoulias V; Mavroudis D;
Anticancer Res; 2008; 28(1B):495-500. PubMed ID: 18383891
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.
Qin TJ; Zhao XH; Yun J; Zhang LX; Ruan ZP; Pan BR
World J Gastroenterol; 2008 Sep; 14(33):5210-6. PubMed ID: 18777599
[TBL] [Abstract][Full Text] [Related]
14. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A
Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
Vici P; Sergi D; Pizzuti L; Mariani L; Arena MG; Barba M; Maugeri-Saccà M; Vincenzoni C; Vizza E; Corrado G; Paoletti G; Tomao F; Tomao S; Giannarelli D; Di Lauro L
J Exp Clin Cancer Res; 2013 Aug; 32(1):49. PubMed ID: 23927758
[TBL] [Abstract][Full Text] [Related]
17. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].
Yang J; Shi Y; He X; Zhou S; Dong M; Liu P; Zhang C; Qin Y; Yang S; Gui L
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):137-40. PubMed ID: 24796464
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience.
Cassier PA; Walter T; Eymard B; Ardisson P; Perol M; Paillet C; Chayvialle JA; Scoazec JY; Hervieu V; Bohas CL
Cancer; 2009 Aug; 115(15):3392-9. PubMed ID: 19472402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
